Armistice reports 2.0M shares (4.3%) in Avanos
Avanos Medical, Inc. ownership update: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 2,000,000 shares of common stock, representing 4.30% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Avanos Medical, Inc. ownership update: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 2,000,000 shares of common stock, representing 4.30% of the class. The filing states Armistice Capital, as investment manager to the Armistice Capital Master Fund Ltd., exercises shared voting and dispositive power over those shares. The Master Fund is the direct holder and disclaims direct beneficial ownership due to its investment management agreement with Armistice Capital. The joint filing is signed by Steven Boyd on May 15, 2026.
Insights
Armistice reports a passive 4.30% stake via its master fund.
The filing shows 2,000,000 shares held by Armistice Capital Master Fund Ltd., with Armistice Capital exercising shared voting and dispositive power under an Investment Management Agreement. The Master Fund disclaims beneficial ownership because it lacks voting/dispositive authority.
Implications depend on holder intentions and any future amendments; subsequent filings would disclose changes in voting power or holdings.
Key Figures
Key Terms
Investment Management Agreement regulatory
Beneficially own financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Armistice Capital report in AVNS?
Who signed the Schedule 13G/A for AVNS?
Does the filing indicate sole voting or dispositive power?
AI-generated analysis. How Rhea-AI works. Not financial advice.